Interview with the Innovators

Optimizing Communication Between Oncologists and Pathologists on Cancer Biomarker Testing

Video Library —July 18, 2018
Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.
Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country